Chronic Diseases
Chronic diseases are long-lasting (or slowly emerging) conditions, often requiring ongoing medical attention and featuring periods of remission and relapse. A rapid rise in chronic diseases has imposed great health, social, and economic costs, as well as contributing to an overburdened healthcare system.
Why do we expect obesity medicines to work differently?
5 March 2026
Weight regain after stopping GLP-1 medicines isn’t a treatment failure — it shows that obesity is a chronic, relapsing condition. Like other long-term therapies, benefits last only while treatment continues. Reframing obesity this way can improve outcomes and reduce stigma.
The case for adopting a broader perspective on value in Health Technology Assessment
3 March 2026
In this Whitepaper, we describe different perspectives that can be adopted in Health Technology Assessment (HTA), and some of the advantages and disadvantages of these different…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple myeloma and cancer as a whole. The…
Altering the trajectory of HIV in Europe
22 May 2025
Despite substantial medical advancements that have transformed HIV into a manageable chronic condition for individuals, the epidemic remains a pressing public health concern in Europe.
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
Today marks Rare Disease Day 2025. This time last year we published an Article entitled “ Why do we care about rare?”, summarising the origins of…
OHE’s submission for the DHSC’s next 10 years of planning
9 December 2024
This Insight summarises the recommendations OHE submitted towards the Department of Health & Social Care’s consultation on the next 10 years of planning for the NHS.
A Spotlight on Haemophilia Therapies
3 October 2024
Pharmaceutical innovation is a key driver of improvements in health outcomes, quality of life and productivity for people with acute and chronic conditions.
Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
26 June 2024
Our literature review suggests that there are more than 100 inequalities impacting on people living with dementia and their carers across multiple characteristics, circumstances, and in various parts of the health and care system. However, the current low availability and quality of data is a major barrier to accurately measuring these inequalities. With the expectation that 1 in 2 people will be affected by dementia during their lifetime, there is a pressing need for further research to inform future policy, research, and service interventions.